Johnson & Johnson (NYSE:JNJ) Shares Sold by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,890 shares of the company’s stock after selling 629 shares during the period. Mesirow Financial Investment Management Inc.’s holdings in Johnson & Johnson were worth $17,917,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. IFS Advisors LLC grew its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the period. Bay Harbor Wealth Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $32,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the third quarter valued at $35,000. Activest Wealth Management acquired a new position in shares of Johnson & Johnson in the third quarter worth about $40,000. Finally, NewSquare Capital LLC boosted its stake in shares of Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock worth $42,000 after acquiring an additional 172 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 19th. Argus raised Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Finally, Barclays lifted their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $171.33.

Johnson & Johnson Stock Up 0.6 %

Shares of NYSE:JNJ opened at $166.81 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The stock has a market cap of $401.61 billion, a P/E ratio of 25.08, a PEG ratio of 2.56 and a beta of 0.47. The business has a fifty day moving average of $152.95 and a two-hundred day moving average of $156.30. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Johnson & Johnson’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the business earned $2.29 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a $1.24 dividend. The ex-dividend date was Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 2.97%. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In related news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was bought at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.